Schrödinger (SDGR) Competitors $18.03 -0.84 (-4.45%) Closing price 04:00 PM EasternExtended Trading$18.97 +0.94 (+5.21%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SDGR vs. AXSM, BPMC, TLX, KRYS, ELAN, VRNA, NUVL, GRFS, PCVX, and CYTKShould you be buying Schrödinger stock or one of its competitors? The main competitors of Schrödinger include Axsome Therapeutics (AXSM), Blueprint Medicines (BPMC), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Krystal Biotech (KRYS), Elanco Animal Health (ELAN), Verona Pharma (VRNA), Nuvalent (NUVL), Grifols (GRFS), Vaxcyte (PCVX), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Schrödinger vs. Axsome Therapeutics Blueprint Medicines Telix Pharmaceuticals Limited American Depositary Shares Krystal Biotech Elanco Animal Health Verona Pharma Nuvalent Grifols Vaxcyte Cytokinetics Schrödinger (NASDAQ:SDGR) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk. Do analysts recommend SDGR or AXSM? Schrödinger presently has a consensus price target of $32.29, indicating a potential upside of 79.07%. Axsome Therapeutics has a consensus price target of $167.64, indicating a potential upside of 69.58%. Given Schrödinger's higher possible upside, analysts plainly believe Schrödinger is more favorable than Axsome Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Schrödinger 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer SDGR or AXSM? In the previous week, Axsome Therapeutics had 26 more articles in the media than Schrödinger. MarketBeat recorded 26 mentions for Axsome Therapeutics and 0 mentions for Schrödinger. Axsome Therapeutics' average media sentiment score of 0.32 beat Schrödinger's score of 0.00 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Schrödinger Neutral Axsome Therapeutics Neutral Does the MarketBeat Community prefer SDGR or AXSM? Axsome Therapeutics received 423 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 70.50% of users gave Axsome Therapeutics an outperform vote while only 57.89% of users gave Schrödinger an outperform vote. CompanyUnderperformOutperformSchrödingerOutperform Votes5557.89% Underperform Votes4042.11% Axsome TherapeuticsOutperform Votes47870.50% Underperform Votes20029.50% Which has more risk & volatility, SDGR or AXSM? Schrödinger has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Do institutionals and insiders hold more shares of SDGR or AXSM? 79.1% of Schrödinger shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 8.6% of Schrödinger shares are owned by company insiders. Comparatively, 22.4% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, SDGR or AXSM? Schrödinger has higher earnings, but lower revenue than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Schrödinger, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSchrödinger$207.54M6.35$40.72M-$2.57-7.02Axsome Therapeutics$385.69M12.50-$287.22M-$5.99-16.50 Is SDGR or AXSM more profitable? Axsome Therapeutics has a net margin of -74.47% compared to Schrödinger's net margin of -91.84%. Schrödinger's return on equity of -35.77% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Schrödinger-91.84% -35.77% -24.51% Axsome Therapeutics -74.47%-223.51%-39.88% SummaryAxsome Therapeutics beats Schrödinger on 10 of the 18 factors compared between the two stocks. Remove Ads Get Schrödinger News Delivered to You Automatically Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SDGR vs. The Competition Export to ExcelMetricSchrödingerPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.32B$6.32B$5.24B$7.07BDividend YieldN/A2.85%4.87%4.05%P/E Ratio-7.716.7221.1817.48Price / Sales6.35186.92356.3585.27Price / Cash37.4265.6738.1634.64Price / Book2.375.576.233.79Net Income$40.72M$141.67M$3.20B$247.10M7 Day Performance-9.67%-11.43%-8.32%-7.32%1 Month Performance-14.47%-14.59%-3.36%-10.19%1 Year Performance-30.79%-18.30%2.72%-7.41% Schrödinger Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SDGRSchrödinger1.8364 of 5 stars$18.03-4.5%$32.29+79.1%-24.2%$1.32B$207.54M-7.71790Gap DownHigh Trading VolumeAXSMAxsome Therapeutics4.6266 of 5 stars$116.63-1.6%$167.64+43.7%+46.8%$5.69B$385.69M-19.47380Analyst ForecastShort Interest ↓Analyst RevisionNews CoverageGap DownBPMCBlueprint Medicines2.6397 of 5 stars$88.51-0.2%$124.95+41.2%-5.6%$5.66B$508.82M-81.95640News CoveragePositive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.76-2.8%$22.00+31.3%N/A$5.65B$783.21M0.00N/ANews CoverageGap DownKRYSKrystal Biotech4.7971 of 5 stars$180.30-2.0%$220.00+22.0%+0.1%$5.19B$290.52M60.30210Analyst RevisionNews CoveragePositive NewsGap DownELANElanco Animal Health3.9021 of 5 stars$10.49+0.7%$15.17+44.7%-37.3%$5.19B$4.44B26.219,800Gap DownVRNAVerona Pharma3.1614 of 5 stars$63.49+1.3%$69.14+8.9%+257.9%$5.13B$42.28M-33.0730Gap DownNUVLNuvalent2.223 of 5 stars$70.92-2.9%$113.10+59.5%-7.7%$5.08BN/A-20.4440News CoveragePositive NewsGap DownGRFSGrifols3.6774 of 5 stars$7.11-2.2%N/A+3.2%$4.89B$7.21B6.0826,300Positive NewsGap DownPCVXVaxcyte2.4993 of 5 stars$37.76-45.6%$147.50+290.6%-53.1%$4.86BN/A-8.21160Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeCYTKCytokinetics3.887 of 5 stars$40.19-6.9%$82.00+104.0%-42.9%$4.76B$18.47M-7.47250Analyst Forecast Remove Ads Related Companies and Tools Related Companies AXSM Competitors BPMC Competitors TLX Competitors KRYS Competitors ELAN Competitors VRNA Competitors NUVL Competitors GRFS Competitors PCVX Competitors CYTK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SDGR) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Schrödinger, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Schrödinger With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
